

Kidney Cancer (Renal Cell Carcinoma) Pathways

Patient Name: _____ Date of Birth: _____
Member Number: _____ Treatment Start Date: _____
Pathology: _____ **Stage:** _____
Line of Therapy: __Neoadjuvant/Pre-Op __Adjuvant/Post-Op **ECOG Performance Status:** _____ **ICD-10 Code:** _____
 __1st Line __2nd Line __3rd Line __3rd Line+
Biomarkers/Characteristics: (Select all that apply)
Renal Cancer Risk: __Poor __Intermediate __Good Prior Therapy: _____

Metastatic Disease | First Line of Therapy (1st Line)

- High dose intravenous (IV) interleukin-2 (IL2, Proleukin) (**clear cell only**)
- Pazopanib (Votrient)
- Sunitinib (Sutent)

Metastatic Disease | First Line of Therapy (1st Line) | Poor Prognosis* or Non-Clear Cell Histology

- Temsirolimus (Torisel)

Metastatic Disease | Second or Subsequent Lines of Therapy (2nd Line+) | Clear Cell Carcinoma

- Nivolumab (Opdivo)†

*Poor prognosis patients have 3 or more of the following predictors of short survival:

- LDH greater than 1.5 x normal
- Hemoglobin less than normal (anemia)
- Corrected serum calcium (Ca) greater than 10 ng/dL
- Less than 1 year from diagnosis to the start of systemic therapy
- Karnofsky performance status \leq 70 (Unable to carry on normal activity or do active work, but able to perform self-care)
- 2 or more sites of organ metastases

†Administered at a dose of 240 mg every 2 weeks or 480 mg every 4 weeks

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

